Survodutide

Human clinical Weight Loss & Metabolism 2 sources

Survodutide is an investigational dual agonist of the glucagon and GLP-1 receptors. Research indicates it significantly reduces body weight and improves liver health in conditions like MASH by suppressing appetite and increasing energy expenditure.

01Dosing reference

Amount

0.6 mg to 4.8 mg

Frequency

Once weekly

Cycle

Continuous use with gradual dose escalation over 20 weeks to reach maintenance dose

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Dual Receptor Activation

Survodutide binds to and activates both the glucagon-like peptide-1 (GLP-1) and glucagon receptors.

Metabolic Modulation

GLP-1 activation reduces appetite and slows gastric emptying, while glucagon receptor activation increases energy expenditure and promotes fat breakdown in the liver.

Weight and Liver Fat Reduction

The combined effects lead to significant weight loss and improvements in liver histology, particularly in metabolic dysfunction-associated steatohepatitis (MASH).

03Human evidence

Up to 14.9% body weight loss over 46 weeks in adults with obesity.

Phase 2 randomized, double-blind, placebo-controlled trial involving adults with a BMI of 27 or greater.

Significant improvement in liver disease without worsening of fibrosis in up to 83% of adults with MASH.

Phase 2 trial evaluating the efficacy and safety of survodutide in patients with biopsy-confirmed MASH and fibrosis.

04Preclinical evidence

Superior weight loss and liver fat reduction compared to GLP-1 mono-agonists.

Diet-induced obesity mouse models evaluating the synergistic effects of dual agonism.

Increased energy expenditure and enhanced lipid metabolism.

Animal studies assessing the specific contribution of the glucagon receptor component.

05What is known vs. unknown

Reasonably established

Acts as a dual agonist targeting both GLP-1 and glucagon receptors.
Demonstrated up to 14.9% weight loss in Phase 2 clinical trials for obesity.
Shows strong potential for treating MASH (metabolic dysfunction-associated steatohepatitis).
Increases energy expenditure in addition to reducing appetite.

Unknowns & limits

Long-term cardiovascular outcomes and safety are still being evaluated in ongoing Phase 3 trials.
The optimal dose escalation strategy to minimize gastrointestinal side effects is still under investigation.

06Safety & regulatory context

Regulatory statusSurvodutide is currently an investigational drug and is not FDA-approved for any indication. It is undergoing Phase 3 clinical trials for obesity and MASH. The safety profile observed in Phase 2 trials is consistent with other incretin-based therapies, with the most common side effects being gastrointestinal in nature, such as nausea, vomiting, diarrhea, and constipation. These side effects are typically mild to moderate and occur most frequently during the dose-escalation phase.

07Compared with Tirzepatide

Survodutide vs. Tirzepatide

Key difference

Tirzepatide is a GLP-1 and GIP receptor agonist, whereas Survodutide is a GLP-1 and Glucagon receptor agonist.

When researchers discuss each

Tirzepatide is discussed for its approved uses in type 2 diabetes and obesity, while Survodutide is often highlighted for its specific potential in treating liver diseases like MASH alongside obesity due to the glucagon component's effect on liver fat and energy expenditure.

08Glossary

Dual Agonist

A compound that binds to and activates two different receptors in the body to produce a combined physiological effect.

MASH

Metabolic dysfunction-associated steatohepatitis, a severe form of fatty liver disease characterized by inflammation and liver cell damage.

Glucagon

A hormone that promotes the breakdown of glycogen to glucose in the liver and increases energy expenditure.

09Knowledge check

Q1Which two receptors does Survodutide target?

Q2What specific liver condition has Survodutide shown significant promise in treating during Phase 2 trials?

Q3Which of the following is a documented limitation of the current Survodutide evidence according to the dossier?

Q4In the dossier's stated comparison with tirzepatide, what specific potential advantage of Survodutide is emphasized?

Q5Which statement best reflects the dossier's regulatory status and common safety observations for Survodutide?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.